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Purpose: To evaluate the visual outcomes of retinoblastoma in the posterior pole (RBPP) treated with chemo-
therapy plus local treatments and to address the prognostic factors that influence such outcomes. 
Methods: The medical records of patients with RBPP diagnosed at the Department of Pediatric Ophthalmology, 
Seoul National University Children’s Hospital between August 1987 and September 2007 were reviewed 
retrospectively. Only those patients treated via primary chemotherapy plus local treatments were included. The 
presence of foveal involvement and tumors in the posterior pole before and after treatment, the type of regression 
pattern and the best corrected visual acuity (BCVA) of each patient were evaluated.
Results: A total of 13 eyes in 12 patients were included. The mean final BCVA for treated RBPP was 20/210 (range, 
hand motion to 20/16). However, eight eyes (61.5%) had an acuity of 20/200 or better and seven eyes (53.8%) 
had an acuity of 20/50 or better. The mean final BCVA was significantly better in cases with negative foveal in-
volvement; however, four eyes (37.5%) with positive foveal involvement had an acuity of 20/200 or better. Tumors 
area in the posterior pole and the type of regression pattern were not significantly related to final BCVA.
Conclusions: Over one half of the studied RBPP patients had working vision. Although the eyes had RBPP with 
positive foveal involvement, about one‐third of the patients had working vision. Vision preservation should be 
considered when deciding on RBPP treatment.
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Retinoblastoma is the most common intraocular tumor in 
children [1]. As the long-term survival rate and eyeball sal-
vage rate of retinoblastoma have increased, attention has be-
gun to focus on treatment that preserves vision [1-4]. 
Chemotherapy plus local treatments have nearly replaced ex-
ternal beam radiotherapy (EBRT) in order to avoid the seri-
ous side effects including secondary malignancy and ocular 
and orbital complications [5-7]. Because the visual potential 
of treated retinoblastoma depends on the location of the tu-
mor [3], the relationship between macular involvement and 
visual prognosis may be an issue. However, studies on the 
visual prognoses of patients with macular retinoblastoma are 
insufficient and controversial. The reported visual acuities of 
the eyes after treatment for macular tumors vary from 20/20 
to no light perception [8-11]. Desjardins et al. [12] reported 
that all eyes with macular retinoblastoma treated with che-
motherapy plus local treatments had an acuity of 20/200 or 
less. Recently, Schefler et al. [13] reported that 57% of mac-
ular retinoblastoma eyes treated with chemotherapy and re-
petitive foveal laser ablation retained 20/80 or better vision. 
We conducted a retrospective study to evaluate the visual 
outcomes of retinoblastoma in the posterior pole (RBPP) 
treated with chemotherapy plus local treatments. Additionally, 
we addressed the prognostic factors that influence visual 
outcomes. Korean J Ophthalmol Vol.24, No.6, 2010
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Fig. 1. Representative fundus photographs of retinoblastoma in the posterior pole (RBPP) according to foveal involvement and tumor area. 
Note that cases with tumors either partially or entirely within the posterior pole at diagnosis were considered as RBPP. (A) A representative 
fundus photograph of RBPP with positive foveal involvement and a tumor larger than half the size of the posterior pole. (B) A representative 
fundus photograph of RBPP with positive foveal involvement and a tumor less than half the size of the posterior pole. (C) A representative fun-
dus photograph of RBPP with negative foveal involvement and a tumor less than half of the size of posterior pole. 
Materials and Methods
All patients with RBPP diagnosed at the Department of 
Pediatric Ophthalmology, Seoul National University Children’s 
Hospital between August 1987 and September 2007 were re-
viewed retrospectively. Only patients treated with primary 
chemotherapy with local treatments such as laser photo-
coagulation or thermotherapy were included. The posterior 
pole was defined as the area within the major vascular ar-
cades, and any tumor partially or entirely within the posterior 
pole at diagnosis was considered as RBPP. Representative 
fundus photographs of the RBPP are shown in Fig. 1. Patients 
who underwent radiotherapy during the disease course were 
excluded.
The first-line chemotherapy regimen consisted of a combi-
nation of cisplatin, etoposide, adriamycin, and cyclophosphamide. 
Thirteen cycles of chemotherapy were administered at 
monthly intervals. The chemotherapy regimens and cycles 
were altered in consideration of drug side effects such as in-
fection, renal dysfunction and tumor responsiveness. 
Diode laser photocoagulation and thermotherapy were 
performed for local control of RBPP. Diode laser photo-
coagulation was used for posterior pole tumors with base 
sizes of five or fewer disc diameters (DD). Thermotherapy 
was used for posterior pole tumors with base sizes of ten or 
fewer DD. Diode laser photocoagulation and thermotherapy 
were not applied at the fovea in order to avoid treatment-re-
lated visual loss.
During the aforementioned period, 154 patients were diag-
nosed with retinoblastoma associated with a posterior pole 
mass. Twenty-three eyes in 19 patients eventually experi-
enced successful tumor control and eyeball preservation via 
primary chemotherapy plus local treatments. Ten eyes in 
seven of these patients were unable to be measured for visual 
acuity due to young age (< 3 years) or developmental delay; 
these patients were excluded from the final analysis. 
Ultimately, a total of 13 eyes in 12 patients were included in 
this study. 
The variables recorded for each eye included age at diag-
nosis and at the final follow-up, gender, duration of fol-
low-up, Reese-Ellsworth classification and International 
Classification of Retinoblastoma at diagnosis, presence of 
foveal involvement, tumor area in the posterior pole, type of 
regression pattern and best corrected visual acuity (BCVA) at 
the final follow-up.
In cases of multiple masses, only masses located in the 
posterior pole were considered. Evaluations of the presence 
of foveal involvement and tumors area in the posterior pole 
were performed both before and after treatment to account 
for tumor shrinkage and scar extension caused by the 
treatment. Tumor area in the posterior pole was measured as 
affected percentage of posterior pole. Post-treatment evalua-
tion was performed based on residua including scar changes. 
The regression patterns were classified as type 0 (no visible 
residua), type I (fully or almost fully calcific residua), type II 
(fleshy tissue with little or no calcification), type III (mixed 
calcific and fleshy), or type IV (atrophic chorioretinal flat 
scar) according to the methods used in a previous study [14]. 
All measurements of visual acuity were performed using a 
standardized Snellen chart. Thereafter, the Snellen visual 
acuities were converted into a logarithmic minimum angle of 
resolution equivalent for statistical analysis. 
The eyes were divided into subgroups of probable visual 
prognostic factors including presence of foveal involvement, 
tumor area in the posterior pole, and type of regression 
pattern. We expected foveal involvement and tumor area in 
the posterior pole to be strong probable prognostic factors. 
The guideline of the International Classification of Retino- 
blastoma can be used as a visual prognostic factor for tumor 
location and size, but it does not sufficiently consider foveal 
involvement or tumor area in the posterior pole. Thus, we in-
vestigated these two factors in patients with RBPP. 
The mean final BCVA and the distribution of final BCVA 
were compared between subgroups of probable visual prog-
nostic factors. The presence of foveal involvement was clas-
sified into two groups: 1) group F (fovea) + represented the 
positive foveal involvement and 2) group F－ represented 
negative foveal involvement. Tumor area in the posterior JM Kim, et al. Visual Prognosis of Treated Macular Retinoblastoma
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Table 1. Probable risk factors and final best corrected visual acuities (BCVA)  
Eye no. Foveal involvement
(group)
*
Posterior pole tumor area 
(group)
† Regression pattern Final BCVA
1 F+ L 0 20/50
2 F+ L I Hand motion
3 F+ L I Finger counting
4 F+ L I Finger counting
5 F+ L I 20/200
6 F+ L III Hand motion
7 F+ L IV 20/320
8F + S I V 2 0 / 2 5
9F － SI 2 0 / 2 0
10 F－ SI I I 2 0 / 5 0
11 F－ S IV 20/20
12 F－ S IV 20/16
13 F－ S I+IV 20/40
*Group F+ represents positive foveal involvement and group F－ represents negative foveal involvement; 
†Group L represents large tumors 
(greater than half of the posterior pole) and group S represents small tumors (less than half of the posterior pole).
Fig. 2. Distribution of final best corrected visual acuity (BCVA) ac-
cording to foveal involvement. Note that the final BCVAs were 
higher in cases of negative foveal involvement. Group F+ repre-
sents positive foveal involvement, and group F－ represents negative 
foveal involvement. 
pole was also classified into two groups: 1) group L (large) 
represented patients with tumor greater than one-half the area 
of the posterior pole and 2) group S (small) represented pa-
tients with tumor less than one-half the area of the posterior 
pole. The representative fundus photographs of the RBPP ac-
cording to this classification are shown in Fig. 1. The types of 
regression patterns were classified according to the afore-
mentioned criteria. Final BCVAs were classified into three 
groups for comparison of the distribution of final BCVA: 1) 
group 1 (good visual acuity) represented visual acuities of 
20/50 or better, 2) group 2 (fair visual acuity) represented vis-
ual acuities of 20/200 or better, but less than 20/50, and 3) 
group 3 (poor visual acuity) represented visual acuities less 
than 20/200. To analyze the influence of tumor area in the 
posterior pole on final BCVA, only eyes with foveal involve-
ment were included. SPSS ver. 17.0 (SPSS Inc., Chicago, IL, 
USA) was used for all statistical analyses. Statistical sig-
nificance was assigned at p <0 . 0 5 .  
Results
The mean age at diagnosis was 9.3 ± 7.4 months (mean ±
SD) for four male patients and eight female patients. The 
mean follow-up period was 79.3 ± 29.3 months, and the 
mean age at the final follow-up was 87.1 ± 32.5 months. 
Two eyes (15.4%) were classified as Reese-Ellsworth clas-
sification group I, nine eyes (69.2%) were classified into 
group II, two eyes (15.4%) as group III, and no eyes were 
classified as Reese-Ellsworth group IV or V. All eyes were 
classified as International Classification of Retinoblastoma 
group B. All patients underwent primary chemotherapy; 
seven also underwent laser photocoagulation, while two un-
derwent accompanying thermotherapy. The presence of fo-
veal involvement and tumor area in the posterior pole were 
not affected by treatments. The mean final BCVA of treated 
RBPP was 20/210 (range, hand motion to 20/16). However, 
eight eyes (61.5%) had an acuity of 20/200 or better and 
seven eyes (53.8%) had an acuity of 20/50 or better. 
All data regarding the probable risk factors and final 
BCVA are listed in Table 1. The only factor found to sig-
nificantly correlate with visual outcome was the presence of 
foveal involvement. Mean final BCVA was significantly bet-
ter in group F－ (five eyes) than in group F+ (eight eyes), with 
averages of 20/26 (range, 20/50 to 20/16) in group F－ and 
20/778 (range, hand motion to 20/25) in group F+ (p = 0.006). 
All eyes in group F－ had an acuity of 20/50 or better, where-
as only four eyes (37.5%) in group F+ had an acuity of 
20/200 or better, as shown in Fig. 2. The representative fun-Korean J Ophthalmol Vol.24, No.6, 2010
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Fig. 3. Representative fundus photographs according to foveal involvement and visual outcome. (A) Eye 4, a representative case 
of retinoblastoma in the posterior pole (RBPP) with positive foveal involvement, showed a poor visual outcome, with a final best 
corrected visual acuity (BCVA) of finger counting at 2 feet. (B) Eye 1 had a final BCVA of 20/50. (B,C) Representative cases 
of RBPP with positive foveal involvement showing fair and good visual outcomes. (C) Eye 8 had a final BCVA of 20/25. (D) A 
representative case of RBPP with negative foveal involvement showing a good visual outcome; eye 11 had a final BCVA of 
20/20. 
dus photographs are presented according to the foveal in-
volvement and visual outcome in Fig. 3.
Other probable prognostic factors were not significantly 
correlated with visual outcome. Mean final BCVA was better 
in group S (1 eye) than in group L (7 eyes), with averages of 
20/25 and 20/1,262 (range, hand motion to 20/50), respectively. 
However, this result was not statistically significant due to 
the small number of cases in group S (p = 0.250). Two eyes 
(28.6%) in group L had an acuity of 20/200 or better, despite 
foveal involvement and large tumors in the posterior pole, as 
presented in Fig. 4.
Mean final BCVA was not significantly different accord-
ing to type of regression. However, eyes with type IV re-
gression patterns tended to have a better final BCVA com-
pared to those of other types in the final BCVA distribution, 
as shown in Fig. 5A. According to the data presented in Fig. 
5B, eyes with type IV regression patterns tended to have less 
frequent foveal involvement and smaller tumor area in the 
posterior pole. 
Discussion 
Several recent treatment advances have led to increased 
eyeball salvage rates in the treatment of retinoblastoma. 
Chemotherapy plus local treatments resulted in nearly 100% 
treatment success in eyes with R-E groups I to IV and avoid-
ing EBRT or enucleation [4]. Thus, the attention paid to the 
visual outcomes of treated retinoblastoma has increased. 
Migdal [10] reported that 50% of bilateral retinoblastoma 
cases had a final visual acuity of 6/12 or better in one eye, and 
Holbek and Ehlers [15] reported that 54% of retinoblastoma 
patients in their study had an acuity of better than 6/12 after 
treatment with EBRT. 
Several authors have presented counterintuitive cases of 
patients with macular tumors and surprisingly good vision 
[9,11,16,17]. The results of previous retrospective studies on 
visual outcomes of treated macular retinoblastoma vary ac-
cording to the definition of macula. Hall et al. [8] reported a 
strong association between tumor location and visual out-
come; however, they simultaneously reported that 33% of 
treated macular tumors (defined as a tumor within 1.5 DD of 
the fovea) had an acuity of 20/40 or better. Desjardins et al. 
[12] also reported a strong association between tumor loca-JM Kim, et al. Visual Prognosis of Treated Macular Retinoblastoma
351
Fig. 4. Distribution of final best corrected visual acuity (BCVA) ac-
cording to tumor size. Group L (large) represents tumors greater 
than half of the size of posterior pole; group S (small) represents tu-
mors less than half of the size of posterior pole. Note that only eyes 
with foveal involvement were included to avoid the influence of fo-
veal involvement.
A B
Fig. 5. Distribution of final best corrected visual acuity (BCVA) and status of foveal involvement and tumor area in the posterior pole accord-
ing to the type of regression pattern. (A) Distribution of final best corrected visual acuity according to the type of regression pattern. Note that 
the eyes with type IV regression patterns tended to have better final BCVAs than did those of other regression types. (B) The distributions of 
foveal involvement and tumor size according to the type of the regression pattern. Note that the eyes with type IV regression patterns tended 
to have less frequent foveal involvements and smaller tumor sizes.
tion and visual outcome, although all eyes with maculopathy 
due to retinoblastoma had a post-treatment acuity of 20/200 
or less [12]. Schefler et al. [13] reported that 57% of macular 
retinoblastomas (defined as tumors within the vascular ar-
cades) treated with planned chemotherapy and repetitive fo-
veal laser ablation had an acuity of 20/80 or better. In our 
study, the mean final BCVA of RBPP treated with chemo-
therapy plus local treatments was not excellent, but 61.5% of 
eyes with RBPP had an acuity of 20/200 or better and 53.8% 
had an acuity of 20/50 or better. 
In our study, the presence of foveal involvement was a 
strong prognostic factor for visual outcome. Schefler et al. 
[13] reported that all tumors outside the fovea had an acuity 
of 20/40 or better, whereas all tumors in the fovea had an 
acuity of 20/60 or worse. As previously mentioned, Desjardins 
et al. [12] also reported that all eyes with maculopathy caused 
by retinoblastoma had a post-treatment acuity of 20/200 or 
less. However, in our study, four eyes (36.4%) with RBPP 
with positive foveal involvement had an acuity of 20/200 or 
better. This result suggests the treated RBPP can have work-
ing vision, although RBPP involving fovea.
Another logical assumption is that a large tumor assures a 
poor visual prognosis, and a small tumor assures a good visu-
al prognosis. However, we could not demonstrate differences 
in final BCVA according to the tumor area in posterior pole 
because of the small number of cases. Further studies are 
needed that evaluate the influence of tumor size on final visu-
al outcome.
Regression patterns have changed as chemotherapy has re-
placed EBRT as the treatment of choice for retinoblastoma. 
Singh et al. [14] reported the distribution of regression pat-
terns of retinoblastoma treated with EBRT to be 18% for type 
0 tumors, 50% for type I, 17% for type II, and 14% for type 
III; their report contained no comment on type IV regression 
patterns. Shields et al. [18,19] reported the distribution of re-
gression patterns of retinoblastoma treated with chemo-
therapy to be 2% to 3% for type 0 tumors, 10% to 13% for 
type I, 3% to 5% for type II, 23% to 33% for type III, and 
51% to 57% for type IV tumors. In our study, the distribution 
of the regression patterns was similar to those documented in 
previous studies examining patients treated with chemotherapy. 
The relationship between the regression pattern and the final 
visual outcome was not evaluated in previous studies. In our 
study, we were unable to demonstrate a significant difference 
in mean final BCVA according to the type of regression pat-
tern due to the small numbers of cases. However, the eyes 
with type IV regression patterns tended to have better final 
BCVAs. This result is paradoxical because the type IV re-
gression pattern indicates projected sclera for the atrophic 
choroid and retina. However, in previous studies, the re-
gression pattern was associated with tumor size and location 
[14,18,19]. For instance, Shields et al. [19] reported that the 
factors predictive of type IV regression patterns were smaller Korean J Ophthalmol Vol.24, No.6, 2010
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tumor base and greater distance from the foveola. These fea-
tures were also observed in our study. The relatively good 
visual outcomes of the type 4 regression patterns may be due 
to these features. 
In our study, foveal involvement and tumor area in posteri-
or pole were not changed by treatments. However, in some 
cases, a large fusiform-shaped RBPP that hid the fovea at the 
initial examination and without foveal involvement at the tu-
mor base decreased after treatment. This finding suggests 
that large RBPPs hiding the fovea at initial examination can 
shrink after treatment and preserve the fovea. Therefore, we 
must consider the possibility of vision preservation in cases 
of RBPP, even though large RBPPs may obscure most of the 
posterior pole.
There are several limitations to the present study. First, the 
sample size was small, as we had to exclude many patients 
for which we had no visual acuity scores due to young age, 
developmental delays, or primary enucleation. Second, our 
study included eyes with multiple tumors, although only 
RBPP was considered in these cases. However, tumor re-
growth, seedings, tractional or serous retinal detachments 
and retinal pigment epithelial atrophy surrounding the tumor 
can affect the central vision even if the tumor is outside of the 
posterior pole. Third, visual outcomes were assessed only ac-
cording to central visual acuity. Other analyses of visual 
function, such as a contrast-sensitivity test or a visual field 
test, could also be used. Further studies taking these above is-
sues into account are needed.
Retinoblastoma patients now have an excellent prognosis, 
both for survival and eyeball preservation. Although visual 
prognosis is strongly correlated with the presence of foveal 
involvement, the visual outcomes of RBPP cannot be easily 
predicted. Thus, the possibility of preserving vision should 
be considered before making treatment decisions. Additionally, 
active efforts to improve visual function in retinoblastoma 
must be taken into account, such as via occlusion therapy and 
through close follow-up of visual acuity [20]. 
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